Related Experiment Video
Updated: Feb 28, 2026

Three-Dimensional 3D Tumor Spheroid Invasion Assay
Published on: May 1, 2015
Pleiotropic Effects of 3-O-Decanoylquercetin on U373-MG Human Glioma Cell Line
Paola Dell'Albani1, Valentina La Cognata1, Sebastiano Alfio Torrisi2
1Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), Via P. Gaifami, 18, 95126 Catania, Italy.
Abstract:
Gliomas are among the most challenging brain tumors to treat, owing to their marked heterogeneity and the aberrant signaling networks that sustain tumor growth and resistance to therapy. Quercetin, a dietary flavonoid widely found in fruit and vegetables, exhibits documented anticancer activity, prompting the development of optimized derivatives with improved biological potency. In earlier work, we synthesized and evaluated a series of quercetin derivatives and identified the acylated compound 3-O-decanoylquercetin (Q-3-Dec) as particularly effective in reducing glioma cell viability. In this study, we explored Q-3-Dec as a multi-target agent, which concomitantly impairs NF-κB/STAT3-dependent survival signaling, mitochondrial function, and O6-Methylguanine-DNA Methyltransferase (MGMT) expression, a DNA repair enzyme closely associated with chemoresistance, in glioma cells. In U373-MG glioma cells, treatment with 50 μM Q-3-Dec triggered pronounced, time-dependent morphological changes and an early loss of mitochondrial membrane potential after 3 h. With prolonged exposure, Q-3-Dec markedly decreased NF-κB and STAT3 phosphorylation and reduced the expression of the anti-apoptotic proteins Bcl-2 and survivin, alongside a significant decrease in MGMT levels. These combined effects culminated in a progressive increase in cell death, reaching approximately 30% after 48 h. Together, these findings position Q-3-Dec as a multi-node modulator of glioma survival, supporting its potential for further preclinical development to improve future therapeutic strategies against glioma.
Insights
A quercetin derivative, Q-3-Dec, shows promise against brain tumors called gliomas. It targets multiple cancer survival pathways and DNA repair mechanisms, leading to increased glioma cell death.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Gliomas are aggressive brain tumors with complex signaling pathways driving growth and treatment resistance.
- Quercetin, a natural flavonoid, has anticancer properties, leading to the development of enhanced derivatives like Q-3-Dec.
- O6-Methylguanine-DNA Methyltransferase (MGMT) is a DNA repair enzyme linked to glioma chemoresistance.
Purpose of the Study:
- To investigate the multi-target effects of 3-O-decanoylquercetin (Q-3-Dec) on glioma cells.
- To assess Q-3-Dec's impact on survival signaling, mitochondrial function, and MGMT expression in gliomas.
- To evaluate Q-3-Dec's potential as a therapeutic agent for glioma.
Main Methods:
- Treatment of U373-MG glioma cells with Q-3-Dec.
- Assessment of morphological changes and mitochondrial membrane potential.
- Analysis of NF-κB and STAT3 phosphorylation, Bcl-2, survivin, and MGMT expression.
- Quantification of cell death over 48 hours.
Main Results:
- Q-3-Dec induced significant morphological changes and mitochondrial dysfunction in glioma cells.
- Treatment reduced NF-κB and STAT3 signaling, and decreased levels of anti-apoptotic proteins (Bcl-2, survivin) and MGMT.
- A progressive increase in glioma cell death, reaching approximately 30% at 48 hours, was observed.
Conclusions:
- Q-3-Dec acts as a multi-node modulator of glioma cell survival.
- The compound effectively targets key pathways involved in glioma growth and chemoresistance.
- Q-3-Dec demonstrates potential for further preclinical development in glioma therapy.
More Related Videos
09:17Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
Published on: September 16, 2019
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021